Brugia malayi

Elephantiasis (Lymphatic Filariasis) Pipeline Review, H1 2019 Edition - ResearchAndMarkets.com

Retrieved on: 
木曜日, 8月 8, 2019
Health, Infectious diseases, Infectious diseases, Medical specialties, Medicine, Neglected diseases, Tropical diseases, Spirurida, Lymphatic filariasis, RTT, Filariasis, Elephantiasis, Filarioidea, Brugia malayi

The "Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Elephantiasis (Lymphatic Filariasis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Elephantiasis (Lymphatic Filariasis) and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Elephantiasis (Lymphatic Filariasis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.